Recombinant SARS-CoV-2 Nucleocapsid antibody

Catalog No. ABIN7566446

The Human Monoclonal anti-SARS-CoV-2 Nucleocapsid antibody has been validated for ELISA. It is suitable to detect SARS-CoV-2 Nucleocapsid in samples from SARS Coronavirus-2 (SARS-CoV-2).

Quick Overview for Recombinant SARS-CoV-2 Nucleocapsid antibody (ABIN7566446)

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Antibody Type: Recombinant Antibody

Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Host: Human

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Nucleocapsid antibody is un-conjugated

Application: ELISA

Clone: Capsi-1

Product Details anti-SARS-CoV-2 Nucleocapsid Antibody

Purpose: anti-SARS-CoV-2 N Protein, mAb (rec.) (Capsi-1) (preservative free)

Characteristics:

Recombinant Antibody. Recognizes and binds to recombinant SARS-CoV-2 N protein. Application: ELISA. Liquid, in PBS ( pH 7.4). Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.

Purification: Puified

Purity: >95 % (SDS-PAGE)

Endotoxin Level: <1EU/mg (LAL method)

Immunogen: Recombinant SARS-CoV-2 nucleocapsid protein.

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: Liquid, in PBS ( pH 7.4).

Preservative: Without preservative

Handling Advice: Avoid freeze/thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment:

+4°C

Stable for at least 1 year after receipt when stored at -20°C.

Target Details for SARS-CoV-2 Nucleocapsid

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Alternative Name: SARS-CoV-2 N Protein

Target Type: Viral Protein